Imaging Study Using 68Ga-HA-DOTATATE for Suspected Somatostatin Receptor Positive Tumors
Tests a PET imaging agent in people with suspected neuroendocrine tumors.
Plain-language title generated from the registry record
Registry title: 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
Key facts
- Where
- Edmonton, CanadaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with known or suspected tumors that carry somatostatin receptors, such as neuroendocrine tumors. They will have a 68Ga-HA-DOTATATE PET scan.
- Sex
- All sexes can join.
- Disease stage
- Known or clinically suspected somatostatin receptor positive tumors, for example gastrointestinal, pancreatic or lung neuroendocrine tumors, pheochromocytoma, paraganglioma, medullary thyroid cancer, medulloblastoma or meningioma.
- Biomarker or test result
- Tumors that are known or suspected to be somatostatin receptor positive.
Main reasons for not taking part
- Weight over 225 kg (496 lb)
- Cannot be scanned or cannot lie still for imaging
- Earlier allergic reaction to DOTATATE or somatostatin analogues
- No intravenous access
- Another illness or situation that could interfere with the study, in the investigator's opinion
Read by machine on 12 November 2026.
Where in Canada
- University of AlbertaEdmonton, CanadaContact: Jonathan Abele, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Alberta
- Trial code
- NCT04888481
- Record updated
- 11 May 2026
- Original description
Somatostatin receptor (SSR) imaging is a critical component of clinical care for many patients being investigated for or with confirmed SSR positive tumors. In the past, 111In-octreotide imaging has been used for this purpose but it has been recently supplanted globally by SSR positron emission tomography (PET) imaging due to better image quality and higher diagnostic accuracy.Read full original descriptionShow less
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
Somatostatin receptor (SSR) imaging is a critical component of clinical care for many patients being investigated for or with confirmed SSR positive tumors. In the past, 111In-octreotide imaging has been used for this purpose but it has been recently supplanted globally by SSR positron emission tomography (PET) imaging due to better image quality and higher diagnostic accuracy.
This study will assess the safety and diagnostic effectiveness of 68Ga-HA-DOTATATE produced a the Edmonton Radiopharmaceutical Centre (ERC).
Inclusion: Patients with known or clinically suspected somatostatin receptor positive tumors including but not limited to: gastrointestinal neuroendocrine tumors, pancreatic neuroendocrine tumors, pulmonary neuroendocrine tumors, neuroendocrine tumors - primary unknown, pheochromocytoma, paraganglioma, medullary thyroid cancer, medulloblastoma, meningioma; A standard clinical CT or MRI is obtained within 6 months of enrollment; Ability to provide written informed consent prior to participation in the study (participant or if required a legal medical decision maker).
Exclusion: Previous allergic reaction to DOTATATE or somatostatin analogues; Any additional medical condition, serious inter-current illness, or other extenuating circumstance that, in the opinion of the investigator or attending department physician, may significantly interfere with study performance or interpretation; Weight > 225 kg (weight limit of the PET/CT scanner); Inability to scan (ie. extreme claustrophobia) or inability to lie still for imaging; Lack of intravenous access.